• Skip to main content
  • Skip to primary sidebar

Dr. Steven Davis

Davis Cosmetic Plastic Surgery

  • Home
  • About
    • Meet Dr. Davis
    • Meet Our Staff
    • What Our Patients Say
    • FAQ
  • Procedures
    • Face Procedures
    • Breast Procedures
    • Body Procedures
    • HALO
    • Coolsculpting
    • Skin Procedures
    • Male Procedures
  • From Dr. Davis
    • Articles
    • Podcasts
      • The Plastic Surgery Revolution
      • Dr. Davis Video Series
    • Media
      • Dr. Davis Video Series
      • In The Media
      • Television Appearances
      • Dr. Davis on the Radio
      • Davis CPS In The News
      • Print Articles / Publications
  • Photos
  • Shop
  • Contact
    • Cherry Hill, NJ Location
    • Northfield, NJ Location
    • Philadephia, PA Location
  • 856-424-1700

As Interest in Neurotoxin Injections Soars, a New Option Enters the Mix: Jeuveau

December 17, 2019 by Davis

If you’ve ever consulted a plastic surgeon about smoothing your fine lines with injectables, you were probably presented with one or two options—three, at most—because that was the number of FDA-approved neurotoxins on the market.

That changed this year with the approval of Jeuveau for the treatment of moderate to severe glabellar lines, or “frown lines,” as they’re more widely known. You may be thinking, What’s the big deal?

As Interest in Neurotoxin Injections Soars, a New Option Enters the Mix: Jeuveau

Well, Jeuveau, which is structurally similar to Botox, is the first new brand of neurotoxin to come to the US market in almost 10 years, and that’s pretty remarkable when you consider the demand for neurotoxin injections. In 2018, nearly 7.5 million Botox, Dysport, Xeomin injections were administered in the United States, according to the American Society of Plastic Surgeons (ASPS), making it the most popular minimally-invasive procedure at a time when interest in every kind of facial filler is exploding.

So, any new option is bound to generate lots of buzz.

Even more, the demographic that’s growing the fastest is the under-30 age bracket. Neurotoxin injectable procedures have increased 28% among 20- to 29-year-olds since 2010, according to the ASPS.

Evolus, the California-based company that manufactures Jeuveau, is responding to that budding demand by positioning itself as a self-described “performance beauty” company, rather than a traditional drug maker.

As a quick refresher on how injectable neurotoxins work, they smooth wrinkles by temporarily paralyzing the underlying facial muscles, which sounds much scarier than it actually is. The technical name for these formulas—which you may recognize from the endless stream of online, TV, and magazine ads—is botulinum toxin type A.

While Jeuveau is only approved, for the time being, to treat the appearance of frown lines in adults, it had a higher satisfaction rate than Botox in a recent head-to-head, blind trial.

Curious about what Jeuveau could do for you? Davis Cosmetic Surgery is the exclusive Jeuveau provider for the Delaware Valley, including South Jersey and Philadelphia. Schedule a consultation with board-certified plastic surgeon Dr. Steven Davis to find out whether you’re a candidate for the treatment.

Spread the love

Filed Under: Articles

Primary Sidebar

Follow Us

Contact Us

  • This field is for validation purposes and should be left unchanged.

© 2023 · Davis Cosmetic Plastic Surgery • Privacy Policy • New Jersey Web Design by Trinity Web Media